In a groundbreaking development in genetic medicine, a baby born with a rare and life-threatening genetic condition is now thriving after receiving a pioneering, personalized gene editing therapy. The case, detailed in a recent study published in the New England Journal of Medicine, represents one of the first successful uses of a custom treatment designed to correct a tiny but critical mutation in the genetic code that otherwise proves fatal for half of the affected infants.
The infant, KJ Muldoon of Clifton Heights, Pennsylvania, was diagnosed shortly after birth with severe CPS1 deficiency, a rare disorder estimated to affect about one in a million babies. CPS1 deficiency impairs the body’s ability to remove ammonia, leading to toxic build-up in the blood. Without effective treatment, many infants face dire outcomes. While liver transplants can sometimes help, the procedure is invasive and not always feasible.
KJ’s parents, Kyle and Nicole Muldoon, shared the difficult decisions they faced early on. “We were, like, you know, weighing all the options, asking all the questions for either the liver transplant, which is invasive, or something that’s never been done before,” Nicole recalled. Kyle added, “We prayed, we talked to people, we gathered information, and we eventually decided that this was the way we were going to go.”
Within six months, a team at Children’s Hospital of Philadelphia (CHOP) and Penn Medicine developed a custom therapy using CRISPR-based gene editing technology. Unlike earlier CRISPR methods that cut DNA strands, this therapy employs “base editing,” a technique that flips the mutated DNA “letter” to the correct one, reducing the risk of unintended changes.
Dr. Kiran Musunuru, a gene editing expert at the University of Pennsylvania and co-author of the study, said, “This is the first step towards the use of gene editing therapies to treat a wide variety of rare genetic disorders for which there are currently no definitive medical treatments.”
The therapy was administered to KJ via intravenous infusions starting in February, using lipid nanoparticles to deliver the gene editor directly to liver cells. Dr. Rebecca Ahrens-Nicklas, a gene therapy specialist at CHOP and study author, recalled the treatment day: “He slept through the entire thing.”
Following additional doses, KJ has shown remarkable progress. He is eating more normally, recovering well from minor illnesses, and requires less medication. His mother reflected emotionally, “Any time we see even the smallest milestone that he’s meeting – like a little wave or rolling over – that’s a big moment for us.”
Despite these encouraging signs, researchers caution that long-term monitoring is essential. “We’re still very much in the early stages of understanding what this medication may have done for KJ,” said Dr. Ahrens-Nicklas. “But every day, he’s showing us signs that he’s growing and thriving.”
The implications of this success extend beyond KJ’s case. Rare diseases affect an estimated 350 million people worldwide, most caused by genetic mutations. However, gene therapies often focus on more common conditions due to high development costs and market considerations.
Musunuru emphasized the potential for broader application: “The cost was not far off from the $800,000-plus for an average liver transplant and related care. As we get better and better at making these therapies and shorten the time frame even more, economies of scale will kick in and I would expect the costs to come down.”
Experts agree that this research sets a new benchmark. Senthil Bhoopalan of St. Jude Children’s Research Hospital, who was not involved in the study, called it “very exciting” and said, “This really sets the pace and the benchmark for such approaches.”
Carlos Moraes, neurology professor at the University of Miami, added, “Once someone comes with a breakthrough like this, it will take no time for other teams to apply the lessons and move forward. There are barriers, but I predict that they are going to be crossed in the next five to 10 years.”
This landmark case shines a hopeful light on the future of personalized gene therapies, offering the promise that even the rarest and most devastating genetic diseases may one day be treatable.
Source: New England Journal of Medicine; Interviews with Dr. Kiran Musunuru, Dr. Rebecca Ahrens-Nicklas, and experts in gene therapy.
Edgaroo Hernal started college at UP Diliman and received his BA in Economics from San Sebastian College, Manila, and Masters in Information Systems Management from Keller Graduate School of Management of DeVry University in Oak Brook, IL. He has 25 years of copy editing and management experience at Thomson West, a subsidiary of Thomson Reuters.
- EDGARDO HERNALhttps://tutubi.ph/author/gary-hernal/
- EDGARDO HERNALhttps://tutubi.ph/author/gary-hernal/
- EDGARDO HERNALhttps://tutubi.ph/author/gary-hernal/
- EDGARDO HERNALhttps://tutubi.ph/author/gary-hernal/
